Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DKY709 + spartalizumab
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
DKY709 + spartalizumab is an investigational combination therapy for advanced solid tumors, particularly evaluated in patients with non-small cell lung cancer (NSCLC), melanoma, and nasopharyngeal carcinoma (NPC)[1][2]. DKY709 is a novel immunomodulatory agent whose precise mechanism is not yet publicly disclosed, while spartalizumab (also known as PDR001) is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1), thereby inhibiting its interaction with PD-L1 and PD-L2 to promote anti-tumor immune responses[1][3][4][6][7]. The combination is designed to enhance immune-mediated anti-tumor activity through immune checkpoint blockade and additional immunomodulatory effects[1][2][3][7].
- Other names
- DKY709 + PDR001
02
Targets
CRBN (Cereblon)IKZF2PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on DKY709 + spartalizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DKY709 + spartalizumab.